FindTrial
Sign In

Anti cancer therapy in COVID-19 time

The safety of symptom based administration of chemotherapy in cancer patients during the ongoing COVID-19 pandemic

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036590
Enrollment
1000
Registered
2021-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: C00-D49- Neoplasms

Interventions

Control Intervention1: None: None

Sponsors

NCI AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of malignancy (solid, hematologic) Had received any form of systemic therapy (chemotherapy, harmonal, targeted, immunotherapy, metronomic) in between 1st March 2020 to 28th February 2021 Histopathological diagnosis of cancer

Exclusion criteria

Exclusion criteria: Had documented personal or family history of COVID-19 infection prior to systemic therapy administration Patients who had received anti-cancer systemic therapy at different cancer center before registration during the study period

Design outcomes

Primary

MeasureTime frame
To evaluate the risk of COVID-19 related death among cancer patients during the systemic anti-cancer therapyTimepoint: 28th february 2021—

Secondary

MeasureTime frame
To evaluate the risk of COVID-19 related death among cancer patients who received the systemic anti-cancer therapy during the study period To determine the factors associated with COVID-19 related deathTimepoint: 1 year—

Countries

India

Contacts

Public ContactAkash Kumar

NCI AIIMS

akashjha08@yahoo.com9910850134

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026